Cargando…

Monoclonal Antibody Therapies against Anthrax

Anthrax is a highly lethal infectious disease caused by the spore-forming bacterium Bacillus anthracis. It not only causes natural infection in humans but also poses a great threat as an emerging bioterror agent. The lethality of anthrax is primarily attributed to the two major virulence factors: to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Zhaochun, Moayeri, Mahtab, Purcell, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202866/ https://www.ncbi.nlm.nih.gov/pubmed/22069754 http://dx.doi.org/10.3390/toxins3081004

Ejemplares similares

A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague
por: Tao, Pan, et al.
Publicado: (2018)

Role of N-Terminal Amino Acids in the Potency of Anthrax Lethal Factor
por: Gupta, Pradeep K., et al.
Publicado: (2008)

Anthrax Lethal Toxin Downregulates Claudin-5 Expression in Human Endothelial Tight Junctions
por: D’Agnillo, Felice, et al.
Publicado: (2013)

Anthrax Edema Factor Toxicity Is Strongly Mediated by the N-end Rule
por: Leysath, Clinton E., et al.
Publicado: (2013)

Antibodies Against Anthrax: Mechanisms of Action and Clinical Applications
por: Froude, Jeffrey W., et al.
Publicado: (2011)

Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed
por: Sawada-Hirai, Ritsuko, et al.
Publicado: (2004)

Anthrax Lethal Factor Cleavage of Nlrp1 Is Required for Activation of the Inflammasome
por: Levinsohn, Jonathan L., et al.
Publicado: (2012)

Phage Display Analysis of Monoclonal Antibody Binding to Anthrax Toxin Lethal Factor
por: Goldstein, Jason M., et al.
Publicado: (2017)

A Bivalent Anthrax–Plague Vaccine That Can Protect against Two Tier-1 Bioterror Pathogens, Bacillus anthracis and Yersinia pestis
por: Tao, Pan, et al.
Publicado: (2017)

Anthrax Lethal Factor Cleaves Mouse Nlrp1b in Both Toxin-Sensitive and Toxin-Resistant Macrophages
por: Hellmich, Kristina A., et al.
Publicado: (2012)

Inflammasome Sensor Nlrp1b-Dependent Resistance to Anthrax Is Mediated by Caspase-1, IL-1 Signaling and Neutrophil Recruitment
por: Moayeri, Mahtab, et al.
Publicado: (2010)

Tackling COVID-19 with neutralizing monoclonal antibodies
por: Corti, Davide, et al.
Publicado: (2021)

Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

Anthrax edema toxin disrupts distinct steps in Rab11-dependent junctional transport
por: Guichard, Annabel, et al.
Publicado: (2017)

The Heart Is an Early Target of Anthrax Lethal Toxin in Mice: A Protective Role for Neuronal Nitric Oxide Synthase (nNOS)
por: Moayeri, Mahtab, et al.
Publicado: (2009)

Monoclonal Antibodies Against Bacteria. Volume II
por: Baltimore, Robert S.
Publicado: (1986)

Human monoclonal anti-protective antigen antibody for the low-dose post-exposure prophylaxis and treatment of Anthrax
por: Tang, Qi, et al.
Publicado: (2018)

Monoclonal Antibodies in Cancer Therapy
por: Zahavi, David, et al.
Publicado: (2020)

Susceptibility to Anthrax Lethal Toxin-Induced Rat Death Is Controlled by a Single Chromosome 10 Locus That Includes rNlrp1
por: Newman, Zachary L., et al.
Publicado: (2010)

Antibodies against Anthrax Toxins: A Long Way from Benchlab to the Bedside
por: Avril, Arnaud, et al.
Publicado: (2022)

Anthrax immune globulin improves hemodynamics and survival during B. anthracis toxin-induced shock in canines receiving titrated fluid and vasopressor support
por: Suffredini, Dante A., et al.
Publicado: (2017)

Anthrax Vaccines
por: Splino, Miroslav, et al.
Publicado: (2005)

Imaging of anthrax intoxication in mice reveals shared and individual functions of surface receptors CMG-2 and TEM-8 in cellular toxin entry
por: Merritt, Carly, et al.
Publicado: (2021)

Alternative pre-approved and novel therapies for the treatment of anthrax
por: Head, Breanne M., et al.
Publicado: (2016)

Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus
por: Jin, Jing, et al.
Publicado: (2019)

Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens
por: Zurawski, Daniel V., et al.
Publicado: (2020)

Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax
por: Tournier, Jean-Nicolas, et al.
Publicado: (2019)

Trial watch: Monoclonal antibodies in cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Monoclonal Antibody Therapies for High Risk Neuroblastoma
por: Furman, Wayne L
Publicado: (2021)

Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis
por: Mykoniatis, Ioannis, et al.
Publicado: (2022)

Possible Future Monoclonal Antibody (mAb)-Based Therapy against Arbovirus Infections
por: Sautto, Giuseppe, et al.
Publicado: (2013)

Tackling COVID-19 with neutralizing monoclonal antibodies
por: Corti, Davide, et al.
Publicado: (2021)

Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19
por: Chen, Junsen, et al.
Publicado: (2021)

Roles of Anthrax Toxin Receptor 2 in Anthrax Toxin Membrane Insertion and Pore Formation
por: Sun, Jianjun, et al.
Publicado: (2016)

Human monoclonal antibodies as candidate therapeutics against emerging viruses
por: Jin, Yujia, et al.
Publicado: (2017)

Immunotherapy against Systemic Fungal Infections Based on Monoclonal Antibodies
por: Boniche, Camila, et al.
Publicado: (2020)

Adverse Events of Monoclonal Antibodies Used for Cancer Therapy
por: Guan, Mei, et al.
Publicado: (2015)

Antibody therapy: Substitution-immunomodulation -monoclonal immunotherapy
por: Mehra, Narinder K.
Publicado: (2019)

Monoclonal Antibody-Based Therapies for Myasthenia Gravis
por: Alabbad, Sawsan, et al.
Publicado: (2020)

Insufficient Anthrax Lethal Toxin Neutralization Is Associated with Antibody Subclass and Domain Specificity in the Plasma of Anthrax-Vaccinated Individuals
por: Smith, Kenneth, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dq73175v4lch2hj3vhjl2ff0dg